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Summary 
Bound antibodies can modulate antigen processing but it is not clear to what extent this affects 
antigen presentation. Here we show that presentation of T  cell determinants in tetanus toxin 
can be either enhanced or suppressed as a direct consequence of antibody modulation of antigen 
processing in human B lymphoblastoid cells.  Remarkably, a single bound antibody or its Fab 
fragment can simuhaneously enhance the presentation of one T cell determinant by more than 
10-fold while strongly suppressing the presentation of a different T cell determinant. Biochem- 
ical analysis demonstrates that both the suppressed and boosted determinants fall within an ex- 
tended domain of antigen stabilized or "footprinted" by this antibody during proteolysis. These 
results demonstrate that bound antibodies can modulate the capture of peptides by class II major 
histocompatibility complex (MHC), thus manipulating the T ceU response towards or away from 
particular determinants. Altered processing of protein-protein complexes leading to enhanced 
loading of class II MHC and substantially lowered thresholds for T  cell activation suggests a 
novel mechanism that might reveal "cryptic" self determinants. 
T 
he possibility  that  bound  antibodies might influence 
antigen processing and as a consequence affect its out- 
come at the level of presentation to T  cells, has often been 
raised. Earlier studies showed specific effects on T cell prolifer- 
ation when particular antigen-reactive antibodies were present 
(1-4). At the biochemical level proteolysis of protein-anti- 
body complexes generated persistent protein fragments not 
seen in the absence of antibody. Such effects have been ob- 
served during in vitro digestion of antigen-antibody com- 
plexes  (5,  6) and after antigen uptake into antigen-specific 
human B lymphocytes (7). However no mechanistic connec- 
tion has been made between antibody modulation of pro- 
cessing at the biochemical level and possible outcomes at the 
level of T  cell presentation. 
Recently we showed that the human monoclonal antibody 
11.3 which is known to alter the course of tetanus toxin pro- 
cessing in human B cells (7) could block the appearance of 
a specific T  cell determinant (8).  Interference with loading 
of this determinant (1174-1189) was seen when this antibody 
specificity was present either as an antigen receptor on clone 
11.3 B cells or when taken up in "piggyback" fashion into 
other B cells or macrophages, thus demonstrating that soluble 
antibodies can impose dominant and systemic effects on an- 
tigen processing.  We now report that  this same antibody 
simultaneously boosts by more than 10-fold the loading of 
a second determinant found approximately 100 residues down- 
stream in the tetanus toxin molecule. Further, biochemical 
analysis of the region of antigen stabilized by antibody during 
digestion shows that both the suppressed and boosted deter- 
minants fall within its  "footprint" 
Materials and Methods 
Cell Clones, Antigens, and Antibodies.  EBV-transformed  tetanus 
toxin-specific B cell clones 11.3, 4.2, and 8.5 and autologous T 
cell clones KT30, KT42, KB42, and KB43 were derived and main- 
tained as previously  described  (9). Tetanus  toxin-spedfic B cell clones 
A46 and  FC4 were also grown for antibody production.  The 
specificity  of the T cell clones has been previously described (8-10). 
Human monoclona] antitetanus toxin antibodies were purified from 
concentrated EBV culture supematants by affinity chromatography 
on protein A-Sepharose, and Fabs prepared by digestion of the in- 
tact Ig with papain-agarose followed  by protein A-Sepharose chro- 
matography to remove Fc fragments. B cell clones 4.2, A46, and 
FC4 recognize the toxin B fragment domain (1-864) whereas clones 
11.3 and 8.5 recognize conformational determinants in the C frag- 
ment domain (865-1315). Tetanus toxin (from Wellcome Biotech 
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was purified in monomeric form before use as described previously 
(7). Recombinant C fragment of tetanus toxin (residues 865-1315) 
was prepared as described (11). 
Antigen Presentation Assays.  Graded amounts of antigen and 
different monoclonal human antitetanus antibodies (1/xg/ml un- 
less otherwise stated) were allowed to react in the wells of a flat 
bottom microtiter plate (Costar Corp., Cambridge, MA) for 1 h 
at room temperature before the addition of 2  x  104 T cells and 
2  x  104 irradiated (,~5,000 tad) clone 4.2 EBV-B cells in a final 
volume of 200 #1 RPMI 1640, 10% FCS medium. All antibodies 
recognize nonoverlapping epitopes and do not affect antigen uptake 
by clone 4.2 B cells. Alternatively, B cells were preincubated with 
antigen at 0~  washed, and cultured together with varying con- 
centrations of antibody and 2  x  104 T cells as above. After 48 h 
the cultures were pulsed with 1/zCi [3H]-thymidine (TRA.120; 
Amersham International, Amersham, Bucks, UK) for 16-20 h, and 
the radioactivity incorporated was measured after cell harvesting 
by liquid scintillation counting. 
In  Vitro Transc@tion/Translation and  Antibody~Antigen Foot- 
printing.  Tetanus  toxin C fragment was synthesized by coupled 
transcription/translation  in the Zubay system (Promega Corp., 
Madison, WI) programmed with 4 /~g pTETtac215 (11) DNA 
per 40/~1 reaction and supplemented with either [3H]leucine or 
[3sS]-methionine  (Amersham). Alternatively,  fragment C was puri- 
fied and iodinated as described (7, 11). Translation products or io- 
dinated C fragment were preincubated (90 rain, 0~  with 11.3, 
8.5, or A46 Igs and digested with 10% (wt/wt) trypsin in 0.1 M 
Tris, pH 8.5. At different times the reaction was terminated by 
transfer to 0~  and by the addition of 2 mg/ml BSA. Either the 
complete reaction (A46) or the Ig bound antigen digestion prod- 
ucts (11.3 and 8.5) recovered  on protein A-Sepharose were resolved 
by Tris-tricine SDS-PAGE (7). Those bound to the 11.3 antibody 
were electroblotted onto polyvinyldifluoride (PVDF)  1 membrane 
(ProBlott; Applied Biosystems Inc., Foster City, CA). The labeled 
17-kD, 11.3 bound fragments were detected by autoradiography, 
excised, and subjected to 20 cycles of automated Edman degrada- 
tion in a sequencer (model 470A; Applied Biosystems, Inc.). Ra- 
dioactivity in the phenylthiohydantoins derivatives obtained from 
each cycle was detected by gamma (125I) or scintillation (35S and 
3H) counting. 
Results 
The 11.3 Antibody Boosts Presentation of the I273-1284 De- 
terminant.  The  tetanus  toxin-specific  antibody  11.3 was 
shown earlier to modulate the course of antigen processing 
both in clone 11.3 B ceUs and when added as a soluble piggy- 
back antibody (7).  Recently we showed that this antibody 
strongly suppressed the presentation of T  cell determinant 
1174-1189 in both B calls and macrophages (8).  Since large 
('~16 kD) fragments derived from the 47-kD C  fragment 
domain (residues 865-1315)  of tetanus toxin are stabilized 
during processing of 11.3-tetanus  toxin complexes (7),  it 
seemed possible that other T cell determinants in this region 
might also be affected by binding of this antibody. To gain 
precise control over antibody effects on presentation, we used 
a single tetanus toxin-specific B cell done (4,2)  as the APC 
and modified the substrate processed by these cells by titrating 
Abbreviation used in this paper: PVDF, polyvinyldifluoride. 
in antigen in the presence or absence of 11.3 IgG or alterna- 
tive antitetanus monoclonal Igs. Thus these antibodies, which 
can potentially modulate processing, are taken up bound to 
antigen in piggyback fashion. Autologous T cell clones were 
used to analyze the outcome of processing of these different 
antigen substrates. 
When antibody 11.3 was added as the piggyback specificity 
we observed a striking enhancement (>10 fold) of the pre- 
sentation of a T cell determinant previously mapped between 
residues 1273 and 1284 (10) and restricted by the DRw52a 
class II MHC molecule (Fig. I a, A). Presentation to a number 
of independently isolated T cell clones specific for this deter- 
minant was similarly enhanced (not shown). Several controls 
demonstrated that the lowered threshold for presentation of 
this determinant was not simply due to enhanced antigen 
uptake or to other effects which would generally augment 
antigen presentation.  First, several other antitetanus antibodies, 
including another anti-C fragment specificity (8.5), had no 
effect on the presentation of the 1273-1284 determinant (Fig. 
I a, ^). Second, the presentation of another T cell determinant 
in the C fragment (947-967) recognized by T cell clone KT30 
was unaffected by the presence of the 11.3 antibody (Fig.  1 
a, B). Third, Fab fragments of 11.3 enhanced presentation 
of the 1273-1284 determinant as effectively as intact Ig (Fig. 
1 a, c) also indicating that effects on B cell signaling func- 
tion were not involved and finally, the 11.3 Ig had no effect 
when the T cell determinant was introduced in peptide form 
not requiring processing (Fig. 1 a, D). Thus the 11.3 Ig causes 
a specific modulation of native antigen processing which aug- 
ments T cell epitope presentation in a highly selective manner. 
Although this effect was most clearly dissected using 11.3 
as a piggyback Ig, it could readily be seen when the same 
specificity  was present as a membrane Ig, i.e.,  11.3 B cells 
presented the 1273-84 determinant at significantly lower an- 
tigen concentrations compared with other B cell clones (data 
not shown), confirming the existence of preferred B/T cell 
pairings in this system (8). 
The  Boosting  Effect  Is  Specific  to  the  1273-1284  Deter- 
minant.  Two mechanisms might explain how bound anti- 
bodies enhance presentation. First, they may enhance directly 
by boosting the loading of a particular determinant onto class 
II MHC.  Alternatively, they may enhance presentation in- 
directly, for example by suppressing the production of deter- 
minants that compete for the same MHC class II molecule 
(12). To distinguish between these possibilities  we examined 
the effect of the  11.3 Ig  on  the presentation  of another 
DRw52a-restricted tetanus toxin determinant, recognized by 
T cell clone KT42, which lies in the B fragment of tetanus 
toxin  (1-864,  reference  10). Suppression  of a  competing 
DRw52a binding sequence would be expected to enhance 
all determinants binding to the same class II specificity.  In 
fact, only the 1273-84 determinant was enhanced (Fig.  1 b, 
A) and not the determinant recognized by T cell KT42 (Fig. 
1 b,  B).  Thus,  processing of the antigen/11.3  Ig substrate 
directly augments loading of the 1273-1284  determinant. 
Simultaneous Boosting and Suppression of  Different T Cell De- 
terminants.  Taken together with earlier data (8), these results 
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Figure  1.  Soluble 11.3 antibody selectively enhances presentation of the 1273-1284  determinant by B cell clone 4.2. (a) Proliferative response of clone 
KB42 (1273-1284 specific; (^) clone KT30 (947-967 specific; (B) to tetanus toxin presented by tetanus toxin-specific EBV-B cell clone 4.2 in the absence 
(I-1) or in the presence of antitetanus  Igs 11.3 (,), A46 (A), 4.9 (O), 8.5 (0) all at 1 lgg/ml (7). Proliferative response (c) of T cell clone KB42 
(1273-1284 specific) to tetanus toxin presented by tetanus toxin-specific EBV-B cell clone 4.2 in the absence (CI), or in the presence of antibody 11.3 
(m) or Fab 11.3 (O) at I/zg/ml. Proliferative response (D) of T cell clone KB42 (1273-1284 specific) to tetanus toxin ([-1, m) or peptide 1273-1284 
(O,  O) presented by B cell clone 4.2 in the absence (l-l, O) or in the presence of antibody Ig 11.3 (O,  I)  at 1 ~g/ml. (b) Proliferative response 
of DRw52a-restricted  T cell clones KB42 (^) and KT42 (B) to  tetanus toxin in the presence (J) or absence (I~) of 11.3 antibody. 
indicate that a single antibody can boost the production of 
one T cell determinant (1273-1284) while simultaneously sup- 
pressing a second determinant between residues 1174 and 1189. 
To demonstrate  this  directly we titrated  the  level  of pig- 
gybacked 11.3 Ig while keeping the antigen load constant. 
T cell clones specific for both the above determinants as well 
as for the determinant  947-967 (10) were used to monitor 
the fate of the C fragment/11.3  Ig substrate. A stimulation 
index of 1.0 defined the level of T  cell proliferation  in the 
absence of added Ig. As an increasing proportion of the an- 
tigen load became complexed to 11.3 Ig, presentation of the 
1273-1284 determinant was strongly stimulated while at the 
same time,  presentation  of the  1174-1189 determinant  was 
suppressed (Fig. 2, A and C). At an Ig concentration of 0.5 
/~g/ml, presentation of determinant 1273-1284 was some 20- 
fold enhanced relative to 1174-1189, whereas presentation of 
determinant 947-967 was completely unaffected (Fig. 2, C). 
None of these determinants  was affected when  a different 
tetanus  toxin-antibody  complex was offered as a substrate 
(Fig. 2, B and D). These results provide the fLrst demonstra- 
tion that a single antibody can modulate the outcome of an- 
tigen processing both positively and negatively for different 
T  cell  determinants. 
The Footprint of the 11.3 Antibody Includes both Suppressed 
and Boosted Determinants.  We reasoned that the mechanism 
underlying  these antibody-mediated effects on antigen pre- 
sentation might be clarified by analysis of the distinct tetanus 
toxin fragments known to persist in the presence of 11.3 Ig 
(7). Tetanus toxin C fragment-11.3 antibody complexes were 
allowed to form and then  subjected to controlled protease 
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Figure 2.  Simultaneous boosting and suppressive effects on different 
T call determinants by a single antibody. B cell 4.2 was incubated in the 
presence of either 0.6/~g/ml (.4 and B) or 0.15/~g/ml  (C and D) tetanus 
toxin in the presence of variable levels of either 11.3 (A and C) or A46 
(B and D) antitetanus toxin monoclonal  lg. Ig concentrations were chosen 
to range from 10 times above to 10 times below that of antigen. Prolifera- 
tive responses of T cell clones KT30 (947-967; O), KB43 (1174-1189; Q), 
and KB42 (1274-1289; II) were measured, and the response in the absence 
of added antibody set to 1.0. 
1959  Simitsek et al. Figure 3.  The "footprint" of the 11.3 antibody. (a) Tetanus toxin C 
fragment (865-1315), radiolabeled with  '2sI or  biosynthetically with 
[3H]leucine or [3sS]methionine,  was mixed with monoclonal  antitetanus 
toxin antibodies  11.3, 8.5 (anti-C fragment)  or A46 (anti-B  fragment;  1-184) 
and digested  with trypsin for times indicated. After termination of the 
digestion, aliquots of the total digestion  mixture (+,446)  or the Ig-bound 
antigen fragments  (11.3 and 8.5) were resolved by Tris-tricine SDS-PAGE 
('ZSl digestions shown here) and transferred to PVDF membrane. (b) 
Radiosequencing of the 11.3-bound 17 kD fragment, labeled with nsI, 
[3H]Leu or [3sS]Met. The deduced  NH2-terminal sequence of this frag- 
ment is indicated  above the top panel. (c) Sequence of the tetanus toxin 
C fragment  (13, 14) showing  T cell determinants  947-967, 1174-1189, and 
1273-1284 (bold), the tryptic cleavage  site defining  the NH2 terminus of 
the 11.3 protected  fragment (arrowed)  and the deduced  region footprinted 
by antibody 11.3 (boxed). Asterisks  (*) indicate  the cleavage  sites of frag- 
ments generated from similar digestions of 11.3/C fragment complexes 
with hydrolases  released from frozen/thawed lysosomes  purified  on Per- 
coil gradients (15). 
digestion in vitro. As controls, a different C fragment-Ig com- 
plex (8.5 Ig) or C  fragment mixed with a nonbinding anti- 
body (A46) were digested in parallel. The C  fragment was 
labeled either with '25I or biosynthetically with [3H]leucine 
or [3SS]methionine in an in vitro-coupled transcription/trans- 
lation reaction programmed  with  C  fragment DNA  (11). 
Tryptic digestion of complexes formed between  11.3  anti- 
body and the different labeled C  fragment forms yielded a 
distinct 17-kD Ig-bound fragment (Fig. 3 a, lanes 5-8)  similar 
in size to those generated after processing of the same 11.3- 
antigen complex in APCs (7).  The control digestions pro- 
duced either distinct Ig-bound fragments (Fig. 3 a, lanes 9-12), 
again as seen in 8.5 cells (7) or low molecular weight non-Ig 
associated peptides  (Fig.  3  a,  lanes  1-4).  The  17-kD  11.3 
Ig-protected fragment, labeled with ~sI, [3H]Leu or [35S]Met, 
was blotted onto PVDF membrane and subjected to 20 cycles 
of automated Edman degradation. Peaks of '25I and [3H]Leu 
were observed at cycle 13 and at cycles 2 and 6, respectively 
(Fig. 3  b).  No 3ss label was observed in the first 20 cycles. 
Inspection of the amino acid sequence of tetanus toxin C flag- 
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Figure 4.  (a) Summary  of the effects  of the ll.31gonthree 
determinants in  tetanus toxin. The suppressive (-)  and 
boosting (+ + +) effects,  relative  to presentation  by B cell  4.2, 
are seen  when  the 11.3 Ig is present either  in membrane  (i.e., 
in 11.3 B cells) or soluble (piggyback) form. Its effects  are 
therefore  dominant  in other APCs. (b) Hypothetical  scheme 
to explain the fate of the three determinants. Determinant 
type 1 (e.g., 947-67) falls outside the region bound stably 
to antibody  and therefore  is unaffected.  Determinant  type 2 
(e.g., 1174.89) falls  within the protected domain  but either 
fails to be released from Ig in the class II loading  compart- 
ment (MIIC)  oris sterically  hindered  by antibody  from  binding 
class II MHC or is partially  degraded  before release  from  an- 
tibody and productive binding  can take place. Determinant 
type  3 (1273-84) also falls  within the protected  or footprinted 
domain but now its capture is enhanced  either because the 
antibody presents the determinant  in a favorable  conforma- 
tion for direct class II capture  as implied  in the figure  and/or 
because of increased resistance to proteolysis  of this region. 
The membrane Ig is drawn dotted since soluble  piggyback 
11.3 or its Fab reproduces the same effects. 
ment (13, 14) allowed the NH2-terminus of the 11.3 pro- 
tected fragment to be unambiguously assigned to residue 1168 
on the basis of this radio-sequencing data. This is deduced 
from the fact that of three pairs ofleucines four residues apart 
in the C fragment only residues 1169 and 1173 are two and 
six residues downstream of a tryptic cleavage site and seven 
residues upstream of a tyrosine residue.  (Note that tyrosine 
1170 is apparently not labeled by the Iodogen method.) The 
i7-kD apparent molecular mass of the protected tryptic frag- 
ment corresponds very closely to the calculated mass of 17098.3 
daltons for a fragment starting at residue 1168 and extending 
to the COOH-terminus of the tetanus toxin molecule. Thus 
the fragment of tetanus toxin footprinted by the 11,3 Ig en- 
compasses T cell determinants whose capture can be strongly 
favored or disfavored by the bound antibody. Similar foot- 
printing experiments, performed with hydrolases released from 
purified B  cell  Iysosomal fractions (15), gave  a somewhat 
smaller protected fragment of apparent molecular weight 15- 
kD which upon Edman degradation yielded [3H]leucine and 
125I at cycles 14  and  18,  respectively.  Inspection of the C 
fragment sequence reveals that this fragment begins at res- 
idue  1185 which,  interestingly, falls in  the middle of the 
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1174-89 determinant suppressed by the 11.3 Ig. Since [3H]leu- 
cine and 12sI were also observed  to some extent in the two 
subsequent Edman cycles, fragments beginning at residues 
1183 and 1184 may also exist. 
Discussion 
One might predict two possible outcomes for T cell de- 
terminants located within antibody-bound antigen fragments. 
On the one hand loading onto class II MHC molecules might 
be disfavored due to sequestration by Ig. On the other hand 
the longer lifetime of such fragments within the peptide 
loading compartment ought to increase  the probability of 
successful capture by class II, Remarkably, we find both out- 
comes are possible for different determinants within the same 
antibody bound fragment. This suggests that reciprocal rela- 
tionships between B and T cell epitopes may be very difficult 
to predict except in instances  of actual physical overlap be- 
tween them (3). In the context of effects on T cell epitopes 
the footprint made by the B cell's Ig may in fact be more 
relevant since it is clear that a domain of antigen extending 
well beyond the actual contacts made with antibody can be stabilized.  The extended lifetime of this domain perhaps ac- 
companied by efficient ig-mediated transport to the compart- 
ment of peptide loading (16-20), might be expected to confer 
a global advantage to all determinants within it. However, 
determinants sterically constrained by antibody binding may 
fail to benefit. It is relevant that although the 1174-89 deter- 
minant was left intact by tryptic digestion of 11.3/C frag- 
ment complexes (Fig.  3), digestion by lysosomal hydrolases 
trimmed the antibody bound fragment back to residues 1184/5 
destroying half of this determinant (Fig.  3 c and data not 
shown). The location of this determinant at the boundary 
of protease accessibility/antibody protection may explain its 
very poor capture by class II MHC whereas other determinants 
(for example, 1273-1284)  may have an increased likelihood 
of being captured as a result of the increased lifetime of the 
domain as a whole. The effects of the 11.3 antibody on different 
T cell determinants in tetanus toxin and a hypothetical model 
to explain these effects is shown in Fig. 4. However, the pre- 
cise structural relationship between antibody contact sites and 
favored versus disfavored T  cell determinants remains to be 
established. 
Based on our initial biochemical studies (7) we speculated 
earlier that transfer of partially processed antigen from mem- 
brane Ig to class II MHC might take place directly, i.e., in 
the plane of the membrane, without release into the bulk 
phase of the peptide loading compartment (21). Determinants 
able to take advantage of such a mechanism were proposed 
to be particularly favored. Although this remains a possibility, 
our finding that presentation of the 1273-84 determinant is 
boosted by soluble piggybacked 11.3 Ig or its Fab,  clearly 
shows that membrane attachment of Ig is not a requirement 
for Ig-enhanced capture of T  cell determinants. 
The differential effects on the presentation of class II MHC 
determinants observed here suggests that prevailing antibody 
specificities in general may influence the focus of the T cell 
response, in other words that the determinants which domi- 
nate a response may do so, at least in part, through favorable 
antibody effects on processing at the expense of other disfa- 
vored determinants. This has been suggested before (21-23) 
but is dissected here for the first time at the clonal level and 
under conditions where antibody effects on processing are 
clearly distinguished from effects  on uptake.  It  should be 
stressed that effects similar to those reported here are only 
likely to be seen when antibodies remain tightly bound at 
the acidic pH values found in endosomes i.e., only high affinity, 
class-switched antibodies  are likely to be able to influence pro- 
cessing. 
These studies demonstrate that processing of an antigen- 
antibody complex can substantially lower the threshold for 
a T  cell response. As shown in Fig.  1,  at low (40 ng/ml) 
antigen concentrations,  the 1273-1284 determinant is "cryptic" 
inasmuch as its presentation was only detectable when pro- 
cessing was modified by the 11.3 antibody. Several studies 
have documented the existence of subdominant or cryptic 
T cell determinants in foreign and self proteins and have shown 
that T cells specific for such determinants not only exist but 
are capable  of being activated (12, 24-26).  Lehmann et al. 
(27)  have demonstrated "spreading" of a response to such 
cryptic self determinants after primary induction of responses 
to the dominant determinants in myelin basic protein in the 
mouse EAE model (27).  Other studies show that autoreac- 
tive T cells persist in the normal repertoire because their de- 
terminants are inefficiently presented (28).  We suggest that 
enhanced loading onto class II MHC as a direct result of the 
modulated processing of protein-protein complexes may be 
a novel mechanism of revealing otherwise cryptic T cell de- 
terminants to which tolerance has never been established. Such 
a mechanism would operate independently of increased pro- 
tein capture or increased levels of expression of class II MHC, 
adhesion, or costimulatory molecules and might arise,  for 
example when antibodies elicited by foreign antigens cross- 
react with self proteins.  However, such effects need not be 
confined to antibody-antigen complexes but might also occur 
after processing of other protein-protein complexes, for ex- 
ample, those formed between self and viral proteins (29) or 
protein chaperones. 
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